BLI VS CCCC Stock Comparison

Performance

BLI
10/100

BLI returned -83.56% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.49%, it's performance is below average giving it a grade of 10 of 100.

CCCC
10/100

CCCC returned -80.99% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Forecast

BLI
75/100

5 analysts offer 12-month price forecasts for BLI. Together, they have an average target of 0, the most optimistic forecast put BLI at 0 within 12-months and the most pessimistic has BLI at 0.

CCCC

"Forecast" not found for CCCC

Sentiment

BLI
62/100

BLI had a bullish sentiment score of 62.13% across Twitter and StockTwits over the last 12 months. It had an average of 5.53 posts, 0.77 comments, and 1.49 likes per day.

CCCC
64/100

CCCC had a bullish sentiment score of 63.99% across Twitter and StockTwits over the last 12 months. It had an average of 2.17 posts, 0.33 comments, and 0.33 likes per day.

Technicals

BLI
11/100

BLI receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

CCCC
50/100

CCCC receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

BLI
10/100

BLI has missed earnings 7 times in the last 20 quarters.

CCCC
39/100

CCCC has missed earnings 3 times in the last 20 quarters.

Profit

BLI
10/100

Out of the last 10 quarters, BLI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CCCC
10/100

Out of the last 17 quarters, CCCC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BLI
42/100

BLI has had a lower than average amount of volatility over the last 12 months giving it a grade of 42 of 100.

CCCC
40/100

CCCC has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Berkeley Lights, Inc. Common Stock Summary

Nasdaq / BLI

Healthcare

Biotechnology

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.

C4 Therapeutics, Inc. Summary

Nasdaq / CCCC

Healthcare

Biotechnology

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Power up your portfolio